Literature DB >> 12665389

Transient ischaemic attacks : new approaches to management.

Ramesh Madhavan1, Seemant Chaturvedi.   

Abstract

The fact that transient ischaemic attacks are a harbinger for the possible development of ischaemic stroke has been recognised for several decades. However, within the past decade, our concepts regarding transient ischaemic attacks as a distinct entity from stroke and the prognosis for transient ischaemic attack patients have been challenged. In addition, clinical trials have clarified that modern transient ischaemic attack management is more complex than in the past, with the addition of newer pharmacological options to the stroke prevention armamentarium. Recent information regarding newer antiplatelet agents is reviewed in this article, along with results of clinical trials pertaining to warfarin in stroke prevention. The evolving role of statins, ACE inhibitors and estrogen replacement is reviewed. Finally, the appropriate use of surgery following transient ischaemic attacks is outlined. Recent studies have shown that many patients will benefit from a multimodal pharmacological approach following transient cerebral ischaemia, and the potential for combination therapy is highlighted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665389     DOI: 10.2165/00023210-200317050-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  53 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Cigarette smoking as a risk factor for stroke. The Framingham Study.

Authors:  P A Wolf; R B D'Agostino; W B Kannel; R Bonita; A J Belanger
Journal:  JAMA       Date:  1988-02-19       Impact factor: 56.272

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

4.  Infarcts of undetermined cause: the NINCDS Stroke Data Bank.

Authors:  R L Sacco; J H Ellenberg; J P Mohr; T K Tatemichi; D B Hier; T R Price; P A Wolf
Journal:  Ann Neurol       Date:  1989-04       Impact factor: 10.422

Review 5.  Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D Deykin; L Poller; H Bussey
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

6.  A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1997-12       Impact factor: 10.422

7.  Thrombotic thrombocytopenic purpura associated with clopidogrel.

Authors:  C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

9.  Infarcts with a cardiac source of embolism in the NINCDS Stroke Data Bank: historical features.

Authors:  S J Kittner; C M Sharkness; T R Price; G D Plotnick; J M Dambrosia; P A Wolf; J P Mohr; D B Hier; C S Kase; S Tuhrim
Journal:  Neurology       Date:  1990-02       Impact factor: 9.910

10.  Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group.

Authors:  M R Mayberg; S E Wilson; F Yatsu; D G Weiss; L Messina; L A Hershey; C Colling; J Eskridge; D Deykin; H R Winn
Journal:  JAMA       Date:  1991-12-18       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.